[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537860":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":44,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":56,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"DirkJan Hijnen, MD, PhD","CONTACT","0031 10 704 01 10","d.hijnen@erasmusmc.nl",[15],{"facility":16,"status":17,"city":18,"state":7,"zip":7,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Erasmus University Medical Center","RECRUITING","Rotterdam","Netherlands","NL",{"type":22,"coordinates":23},"Point",[24,25],4.47917,51.9225,{"lat":25,"lon":24},[28],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","DirkJan Hijnen","Principal Investigator","100537860",false,"NCT06283316","Systemic Treatments for Alopecia Areata Registry","STA2R","Inclusion Criteria:\n\n* Diagnosed with alopecia areata;\n* Starting\u002Fusing a systemic treatment for alopecia areata;\n* Informed consent for registry participation obtained from patient and\u002For caretaker.\n\nExclusion Criteria:\n\n* Not sufficiently capable of understanding the Dutch language;\n* Not willing to participate.","ALL","16 Years",{"count":42,"type":43},10000,"ESTIMATED","50 Years","OBSERVATIONAL","A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.",[48,49,50,51,52,53,54,55],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis","Hair Loss","Hair Diseases","Alopecia","Alopecia Drugs","Autoimmune Diseases",[48,49,50,57,58],"Systemic treatment","Registry","2024-02-27",{"date":61,"type":62},"2024-02-28","ACTUAL",{"date":64,"type":62},"2024-01-17",{"date":66,"type":43},"2099-12-31",{"name":5,"class":6},1]